CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The Enhanced Epidermal – Antigen Specific Immunotherapy (EE-ASI) project seeks to improve glycemic control in type 1 diabetes through a novel skin-based delivery system. By targeting antigen presenting cells with a specific beta cell epitope, it aims to preserve insulin production and enhance patient acceptance.
Current approaches to improving glycaemic control in type 1 diabetes are centered on increasingly complex insulin delivery systems.
However, less than 30% of patients can achieve target levels of glucose control with this approach even in a clinical trial setting and many patients are either unable or unwilling to make the personal commitment required.
By contrast, preservation of even small amounts of endogenous insulin production, has been shown to improve glycaemic control, reduce hy…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, PARIS
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
United Kingdom, Cardiff
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Israel, NES TZIONA
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Leiden University Medical Center
Netherlands, Leiden
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
